(NASDAQ: VERV) Verve Therapeutics's forecast annual revenue growth rate of 16.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Verve Therapeutics's revenue in 2024 is $11,758,000.On average, 1 Wall Street analysts forecast VERV's revenue for 2024 to be $2,282,806,317, with the lowest VERV revenue forecast at $2,282,806,317, and the highest VERV revenue forecast at $2,282,806,317. On average, 2 Wall Street analysts forecast VERV's revenue for 2025 to be $1,542,775,698, with the lowest VERV revenue forecast at $1,028,517,132, and the highest VERV revenue forecast at $2,057,034,263.
In 2026, VERV is forecast to generate $1,542,775,698 in revenue, with the lowest revenue forecast at $1,028,517,132 and the highest revenue forecast at $2,057,034,263.